{
  "docId": "019dd923-5fed-74f2-a96f-1bdfa0f8925c",
  "docSlug": "bi-42cd9f0525110ab4",
  "documentTitle": "Here's dermatology startup Zerigo's Series B pitch deck",
  "authorId": "Pitchdecks",
  "authorName": "Zerigo Health",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.784,
  "pageNumber": 7,
  "pageCount": 17,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "Uses a process flow diagram to show the patient journey and the specific point of failure (bypassing phototherapy).",
  "elementsJson": [
    "action_title",
    "process_diagram",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5fed-74f2-a96f-1bdfa0f8925c/7",
  "deckHref": "/decks/019dd923-5fed-74f2-a96f-1bdfa0f8925c",
  "deckJsonHref": "/decks/019dd923-5fed-74f2-a96f-1bdfa0f8925c.json",
  "deckAnchorHref": "/decks/019dd923-5fed-74f2-a96f-1bdfa0f8925c#slide-7",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "FDA-CLEARED, EFFECTIVE, GUIDELINE-RECOMMENDED THERAPY IS BYPASSED",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-b667-711e-a962-34e1310f6c69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.86,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Psoriasis Diagnosis -> Topical Treatment -> Targeted Phototherapy -> Biologics/Systemics",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75500705-0266-4ae5-9ee6-e13f5f3bf2c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Treatment Cost: $40,000-$60,000",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-b667-711e-a962-390a4466d092",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.77,
        "y": 0.62
      },
      "kind": "paragraph",
      "text": "Biologic therapies cost $40,000-$60,000 Per Person Per Year",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d6f3d8e-bdd7-49e7-94c5-4a3d3362baae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.29,
        "y": 0.62
      },
      "kind": "paragraph",
      "text": "57% of Psoriasis patients today report being unsatisfied with or fail topical therapy",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68ca6666-2bdb-49cd-8b7d-64df7e7c58f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.06,
        "y": 0.62
      },
      "kind": "paragraph",
      "text": "Approximately 3% of the U.S. population, or 8.0+M people, are affected by psoriasis",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78a58e7d-9779-4981-8352-8374ec7d1a03",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.21,
        "x": 0.52,
        "y": 0.52
      },
      "kind": "paragraph",
      "text": "FDA-CLEARED, EFFECTIVE, GUIDELINE-RECOMMENDED THERAPY IS BYPASSED. In-office phototherapy (3x/week) is inconvenient and time-consuming. Analog legacy home devices – poor adherence & no dosing control.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de8801c2-f942-4a2a-bcfb-13689c5eb034",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.04,
        "y": 0.86
      },
      "kind": "source-note",
      "text": "1. National Psoriasis Foundation. 2. The journey for US psoriasis patients... 3. Fierce Pharma 2019... 4. 2019 CVS CareMark... 5. 2018 ICER Report",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1dc9384-3997-4c48-abc2-da23d1c5f87a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Bypassing Phototherapy Drives Overuse of Expensive Biologics",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "961565d9-4f52-4179-b37a-10fcca17826d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "76e1b8b3-2586-4983-bce8-db0847a2f679",
      "evidence": "Bypassing Phototherapy Drives Overuse of Expensive Biologics",
      "confidence": 0.5
    },
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "92d2da04-aa85-44cc-819b-445edbd7a122",
      "evidence": "FDA-CLEARED, EFFECTIVE, GUIDELINE-RECOMMENDED THERAPY IS BYPASSED. In-office phototherapy (3x/week) is inconvenient and time-consuming.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "customer-journey-map",
      "slug": null,
      "matchId": "012e9eab-5d6b-4cba-8ee9-508d6aa6ab5e",
      "evidence": "Visualizes the patient treatment path from diagnosis to biologics.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 7,
      "from": 6,
      "beatId": "3c129fa5-6b75-43be-9d92-d2f81a2df66f",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "Slides 6-7 highlight pain points and problem statement",
      "position": 1,
      "confidence": 0.9,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "065c9a5b-fd58-4fdf-b24c-97ee5669638d",
      "evidence": "Slides 7-10 discuss the cost of biologics and the need for alternative solutions",
      "position": 0,
      "objective": "Highlight the cost burden of biologics",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}